Ep. 3: Stock Picking and Catalyst Research | Biotech Bulls & Breakthroughs Podcast

What It Covers

Biotech trader Chef Station and BioPharma Catalyst's John Galliano walk through a systematic process for trading small-cap biotech stocks, covering how to identify catalysts using PDUFA dates, conference presentations, and FDA inspection records, followed by a July–August 2025 watch list of roughly 15 tickers across sleep apnea, oncology, and rare disease spaces.

Key Questions Answered

• •Catalyst-Based Entry Framework: Use BioPharma Catalyst's calendar to identify stocks with definitive timelines — PDUFA dates, conference presentations, or IND acceptance windows (typically 30 days after filing). Trade the run-up into these dates rather than holding through binary outcomes. Selling before the catalyst and capturing 20–25% gains consistently outperforms swinging for approval-day home runs, which carry 50–70% downside risk on negative data.
• •Manufacturing Inspection Due Diligence: Nearly 50% of FDA Complete Response Letters stem from CMC (Chemistry, Manufacturing, and Controls) failures, not clinical data. Before holding through a PDUFA, verify the company's manufacturing facility has passed FDA inspection. The FDA's public inspection database shows green (no action required), yellow (pending items), or red (denied) status — a step most retail investors skip entirely.
• •Low-Float Small-Cap Selection Criteria: Target companies with under 500 million market cap, fewer than 10–15 million shares in the float, existing cash runway, and ideally a partnership or buyout-attractive profile. Stocks like Artelo Biosciences (under 1 million float post-reverse split) moved from $6 to $28 on a single data release, demonstrating how constrained share supply amplifies price movement on positive catalysts.
• •Study Type Risk Stratification: Rank data readouts by failure risk before entering a position. Preclinical, pharmacokinetic, and safety/tolerability (Phase 1/1b) data rarely read negative. Phase 2 open-label studies carry moderate risk since management can observe results. Phase 3 efficacy endpoints carry the highest risk — missing statistical significance by a single decimal point (p=0.06 vs. p=0.05) can trigger 60–70% stock drops, making them the least favorable hold-through scenarios.
• •Multiple Catalyst Stacking: Prioritize companies with two or three sequential catalysts within a 30–60 day window. CGTX exemplifies this: an end-of-Phase-2 FDA meeting on July 9, IND acceptance on July 25 (30 days post-June 25 filing), and a breakthrough designation response by August 25. Each date creates an independent run-up opportunity, allowing traders to enter, take partial profits, and re-enter rather than holding a single binary event.
• •Position Sizing and Profit-Taking Rules: Remove either 20% gains or the full initial capital investment from a position once achieved, leaving only house money exposed to further upside. This approach hedges against reversal while preserving participation in continued moves. For higher-conviction holds — companies with two prior Complete Response Letters already cleared — full position retention through a PDUFA is defensible, as triple rejections are historically rare across the FDA approval record.